Original InvestigationPalliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The PAL-HF study was funded by the National Institute of Nursing Research (NINR). Dr. Steinhauser is a Health Scientist with the Center for Health Services Research and Development in Primary Care, Durham VA Medical Center, Durham, North Carolina. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. Dr. Mentz has received research support from the National Institutes of Health (U10HL110312 and R01AG045551-01A1), Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Medtronic, Novartis, Otsuka, and ResMed; honoraria from HeartWare, Janssen, Luitpold Pharmaceuticals, Novartis, ResMed, and Thoratec/St. Jude; and has served on an advisory board for Luitpold Pharmaceuticals, Inc., and Boehringer Ingelheim. Dr. Granger has received research funding from Novartis, Sanofi, Daiichi, Boeringer Ingelheim, and AstraZeneca. Dr. Johnson has received research support from projects funded by the National Institute on Aging (RO1AG042130; K08AG028975). Dr. Krishnamoorthy has worked on projects funded by research grants to the Duke Clinical Research Institute from the NIH, Novartis, Daiichi-Sankyo, and Eli Lilly; and has received support to attend educational conferences from HeartWare, Thoratec, and Medtronic. Dr. Mark has received consulting fees from Medtronic; and has received research funding from Eli Lilly, Bristol-Myers Squibb, Pfizer, AstraZeneca, Merck and Company, Oxygen Theraputics, and Gilead. Dr. Tulsky has received research funding from PCORI (SC 14-1403-13975). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
P.K. Shah, MD, served as Guest Editor-in-Chief for this paper. Barry H. Greenberg, MD, served as Guest Editor for this paper.